Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 8/20 | 0.56 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.45 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6834984 | 1.00 | TYMP (0.56) | TYMPP2RY12ADORA1ADORA2AADORA2B | |
| SCHEMBL30200670 | 1.00 | TYMP (0.56) | TYMPP2RY12ADORA1ADORA2AADORA2B | |
| SCHEMBL6899475 | 0.95 | TYMP (0.56) | TYMPP2RY12ADORA1ADORA2AADORA2B | |
| SCHEMBL7068382 | 0.95 | TYMP (0.54) | TYMPP2RY12ADORA1ADORA2AADORA2B | |
| SCHEMBL6466222 | 0.95 | TYMP (0.54) | TYMPP2RY12ADORA1ADORA2AADORA2B | |
| SCHEMBL6898807 | 0.94 | TYMP (0.55) | TYMPP2RY12ADORA1ADORA2AADORA2B | |
| SCHEMBL6900160 | 0.94 | TYMP (0.56) | TYMPP2RY12ADORA1ADORA2AADORA2B | |
| SCHEMBL7261560 | 0.94 | TYMP (0.56) | TYMPP2RY12ADORA1ADORA2AADORA2B | |
| SCHEMBL23650062 | 0.94 | TYMP (0.58) | TYMPP2RY12ADORA1ADORA2AADORA2B | |
| SCHEMBL6513309 | 0.94 | TYMP (0.58) | TYMPP2RY12ADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580948-B2 | Modulation of forkhead box O1A expression | ISIS PHARMACEUTICALS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130030036-A1 | MODULATION OF FORKHEAD BOX O1A EXPRESSION | DOBIE KENNETH W (US) | 2013-01-31 | — | — | US | disclosed |
| US-8227593-B2 | Modulation of forkhead box O1A expression | ISIS PHARMACEUTICALS, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20120184031-A1 | ANTISENSE INHIBITION VIA RNASE H-INDEPENDENT REDUCTION IN MRNA | ISIS PHARMACEUTICALS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20110039913-A1 | ANTISENSE MODULATION OF HYDROXYSTEROID 11-BETA DEHYDROGENASE 1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| EP-2272958-A1 | Modulation of forkhead box O1A expression | ISIS Pharmaceuticals, Inc. (US) | 2011-01-12 | — | — | EP | disclosed |
| US-20100311824-A1 | MODULATION OF FORKHEAD BOX O1A EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-7816336-B2 | Antisense modulation of hydroxysteroid 11-beta dehydrogenase 1 expression | ISIS PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7229976-B2 | Modulation of forkhead box O1A expression | ISIS PHARMACEUTICALS, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7163927-B2 | Antisense modulation of kinesin-like 1 expression | ISIS PHARMACEUTICALS, INC. (US) | 2007-01-16 | — | — | US | disclosed |
| US-20030225256-A1 | Antisense modulation of pctaire protein kinase 2 expression | ISIS PHARMACEUTICALS INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030225015-A1 | Antisense modulation of Rb2/p130 expression | ISIS PHARMACEUTICALS INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030225019-A1 | Notch1 inhibitors for inducing apoptosis | ISIS PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030225014-A1 | Antisense modulation of PLML expression | ISIS PHARMACEUTICALS INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030225012-A1 | Antisense modulation of transcription factor DP-1 expression | ISIS PHARMACEUTICALS INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030224513-A1 | Antisense modulation of Notch1 expression | ISIS PHARMACEUTICALS INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030220273-A1 | Antisense modulation of phosphodiesterase 4D expression | ISIS PHARMACEUTICALS INC. | 2003-11-27 | — | — | US | disclosed |
| US-20030220275-A1 | Antisense modulation of kinesin-like 1 expression | ISIS PHARMACEUTICALS, INC. | 2003-11-27 | — | — | US | disclosed |
| US-20030212017-A1 | Antisense modulation of farnesyl transferase beta subunit expression | ISIS PHARMACEUTICALS INC. | 2003-11-13 | — | — | US | disclosed |
| US-20030211606-A1 | Antisense modulation of DYRK4 expression | ISIS PHARMACEUTICALS INC. | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130030036-A1 | MODULATION OF FORKHEAD BOX O1A EXPRESSION | FOXO1, FOXO3, FOXK1 | TYMP 1269/4885P2RY12 4678/4885ADORA1 2320/4885 |
| US-20100311824-A1 | MODULATION OF FORKHEAD BOX O1A EXPRESSION | FOXO1, FOXO3, FOXK1 | TYMP 1323/4885P2RY12 4682/4885ADORA1 2206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.